Aerovate Therapeutics, Inc.

NasdaqGM AVTE

Aerovate Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 71.26 M

Aerovate Therapeutics, Inc. Market Capitalization is USD 71.26 M on January 14, 2025, a -86.95% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Aerovate Therapeutics, Inc. 52-week high Market Capitalization is USD 853.01 M on April 01, 2024, which is 1,096.98% above the current Market Capitalization.
Aerovate Therapeutics, Inc. 52-week low Market Capitalization is USD 39.26 M on June 18, 2024, which is -44.91% below the current Market Capitalization.
Aerovate Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 292.90 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: AVTE

Aerovate Therapeutics, Inc.

CEO	Mr. Timothy P. Noyes M.B.A.
IPO Date	June 30, 2021
Location	United States
Headquarters	930 Winter Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key trends

Past 5 years